Ask an Expert

Leave blank for all. Otherwise, the first selected term will be the default instead of "Any".

Question of the Day

Bryan Roth, M.D., Ph.D.
September 16, 2011

There are several novel medications in both early- and later-stage clinical development which hold out hope for new treatment options as well as many in earlier stages of the pipeline. If only one of these proved effective (for example Gly-T I inhibitors currently in Phase III trials), we could expect new options within a couple of years. The early stage medications, coming mainly from pharmaceutical companies, are at least 5 years away. A new pan-NIH-initiative to accelerate drug discovery via academic labs could yield fruit, with a fair amount of luck, within the 5-year timeline.

Bryan L. Roth, M.D., Ph.D.
Scientific Council Member
Michael Hooker Distinguished Professor
Director, NIMH Psychoactive Drug Screening Program
University of North Carolina Chapel Hill Medical School

Kafui Dzirasa, M.D., Ph.D. - brain & behavior research expert on schizophrenia
Q What is the next big breakthrough in schizophrenia research?
A Kafui Dzirasa, M.D., Ph.D., of Duke University Medical Center received the... More >
Patrick F. Sullivan, M.D., FRANZCP - Brain & behavior research expert on suicide
Q I think it’s wonderful that you got a consortium of scientists to work together to find answers on schizophrenia. What progress do you expect in the next five years?
A In July 2014, the Psychiatric Genomics Consortium published a landmark... More >